Get notified of page updates

Our Featured Research Page lists cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers. You can do a quick search to filter our featured studies by cancer type, study type or key word, or a more in-depth search through clinicaltrials.gov.

How to Use Our Search and Enroll Tool

Search Results: Treatment + Breast Cancer (22 results)

Printer Friendly Page 1 through 22 of 22
Nipple sparing mastectomy with immediate implant-based reconstruction for women with early-stage breast cancer

Treatment
Nipple sparing mastectomy with reconstruction for women with early-stage breast cancer

A Randomized Study of Robotic-Assisted Nipple Sparing Mastectomy vs. Standard Surgery Nipple Sparing Mastectomy for Early Stage Breast Cancer

This study will compare robotic-assisted nipple sparing mastectomy (NSM) to standard surgery NSM for women with early-stage breast cancer. Eligible women will be randomly placed into one of two groups and either undergo the robotic-assisted procedure or undergo the standard of care open surgery for NSM. Participants will be followed for 5 years.

More info
Immunotherapy and PARP Inhibitor for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with a BRCA Mutation

Treatment
Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation

Combining the Immunotherapy Dostarlimab and PARP Inhibitor Niraparib for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with an Inherited or Tumor BRCA Mutation

This study is looking at the effectiveness of combining a PARP inhibitor called niraparib and an immunotherapy called dostarlimab for treating people with an inherited BRCA mutation (found with genetic testing) or a tumor mutation (found through tumor testing) who have breast, pancreatic, ovarian, fallopian tube or primary peritoneal cancer that is metastatic or advanced and cannot be removed by surgery (unresectable).

More info
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

Treatment
Cancer treatment study for people with advanced solid tumors

TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.

More info
Comparing the Safety and Effectiveness of a New Hormonal Therapy in Patients with HER2-Negative, ER-Positive Early Breast Cancer

Treatment
Treatment study for people with early-stage breast cancer

Comparing the Safety and Effectiveness of a New Hormonal Therapy in Patients with HER2-Negative, ER-Positive Early Breast Cancer

This study is comparing safety and effectiveness of a new drug called giredestrant compared to standard hormone therapy in people with early-stage, ER-positive breast cancer. 

More info
Testing a Targeted Therapy in Combination with Chemotherapy for Advanced Solid Tumors

Treatment
Treatment study for people with advanced cancers

Testing the Targeted Therapy Elimusertib in Combination with Chemotherapy for Advanced Cancers

This study is looking at how well the drug elimusertib (a type of targeted therapy known as an ATR inhibitor) works when combined with chemotherapy for treating people with advanced cancers, including urothelial, ovarian, gastric, endometrial, triple-negative breast cancer and others.

More info
PARP Inhibitor (Niraparib) in Patients with Inherited or Tumor PALB2 Mutations in Advanced Solid Tumors (PAVO)

Treatment
Any advanced or metastatic solid tumor except ovarian or prostate

PARP Inhibitor (Niraparib) in Patients with Inherited or Tumor PALB2 Mutations in Advanced Solid Tumors (PAVO)

PAVO is an open-label Phase II study investigating if the study drug, a PARP inhibitor called niraparib (Zejula), is safe and effective for certain people who have been diagnosed with an
advanced solid tumor with either an inherited or tumor PALB2 mutation.

More info
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

Treatment
Treatment study for people with advanced solid tumors

Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

This study is looking whether the drug Talazoparib (also known as Talzenna) is safe and effective for treating people with advanced solid cancers (including breast, gastric, ovarian, pancreatic, prostate or other solid tumors) in people with an inherited mutation (found through genetic testing) or an acquired mutation (found with biomarker testing) in ATM, ATR, BRCA1, BRCA2, BRIP1, BAP1, BARD1, CDK12, CHEK1, CHEK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or other genes.

More info
Study of Two Drugs in ER+ and/or PR+ Cancers With PI3K and/or PTEN Tumor or Inherited Mutations

Treatment
People with advanced breast or endometrial or ovarian cancer

Study of Two Drugs in ER+ and/or PR+ Cancers With PI3K and/or PTEN Tumor or Inherited Mutations

This study is investigating if the study drug copanlisib, when used in combination with fulvestrant, is safe and effective for people with certain advanced ER-positive and/or PR-positive cancers.  People with PI3K and/or PTEN changes in tumor tissue or inherited mutations are eligible.

More info
NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors

Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer

NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors

This study will test how safe and effective the experimental drug NUV-868 is by itself and in combination with a PARP inhibitor in people with advanced solid tumors. The first part of the study will include people with any solid tumor type, and the second part will include people with triple-negative breast, ovarian, pancreatic or prostate cancers only. 

More info
SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells

Treatment
Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation

SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells

The purpose of this study is to see whether the combination of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous (self) bone marrow stem cell infusion, is safe and effective for treating patients with advanced pancreatic cancer or Stage IV, HER2-negative breast cancer who have a BRCA1, BRCA2 or PALB2 inherited mutation. All of these treatments are given intravenously (by vein). This study is open to people who have already received a PARP inhibitor, as well as those who have not. There are no restrictions on the number of prior treatments a patient has received before enrolling.

More info
Treating Early-Stage Breast Cancer  with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with  a BRCA or PALB2 Mutation

Treatment
Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation

Treating Early-Stage HER2-Negative Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation

This study will look at how well the drugs Niraparib (a PARP inhibitor) and Dostarlimab (an immunotherapy) treat early-stage breast cancer in people with an inherited BRCA1, BRCA2 or PALB2 mutation.  

More info
Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)

Treatment
Advanced ovarian, breast, prostate or pancreatic cancer

Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)

PETRA is studying a new PARP inhibitor AZD5305 taken either alone or combined with other treatments in people with advanced ovarian, breast, prostate or pancreatic cancer with an inherited or tumor mutation in: BRCA1/2, PALB2, RAD51C or RAD51D. The treaments participants receive will depend on their cancer type, mutation and when they join the study.

More info
Targeted Therapy RP-3500 Alone or in Combination with Talazoparib or Gemcitabine in Advanced Solid Tumors with DNA Damage Repair Mutations (TRESR Study)

Treatment
Advanced solid tumors

Targeted Therapy RP-3500 Alone or in Combination with Talazoparib or Gemcitabine in Advanced Solid Tumors with DNA Damage Repair Mutations (TRESR Study)

This study is looking at how well a drug called RP-3500 works either alone or when combined with other cancer treatments in people with different types of advanced cancers with a mutation in one of the following genes: BRCA1, BRCA2, ATM, RAD51B, RAD51C, RAD51D, ATRIP, CHTF8, FZR1, MRE11, NBN, RAD17, RAD50, REV3L, SETD2 or RNASEH2. RP-3500 is a type of oral, targeted therapy known as an ATR inhibitor. The combination prescribed will depend on cancer type and mutation and when people join the study.

More info
ATR Inhibitor Plus Niraparib Study in Advanced Solid Tumors and Ovarian Cancer

Treatment
Advanced ovarian cancer or other solid tumors

ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

This study will look at how well how well people with advanced ovarian, fallopian tube or primary peritoneal cancer or other solid tumors respond to treatment with the targeted therapy BAY1895344 in combination with the PARP inhibitor niraparib.

More info
A Study of the Investigational Targeted Therapy ART4215 to Treat Advanced or Metastatic Solid Tumors

Treatment
Advanced solid tumors

A Study of the Investigational Targeted Therapy ART4215 to Treat Advanced or Metastatic Solid Tumors

This study is looking at how well a drug called ART4215 works either alone or when combined with the PARP inhibitor talazoparib in people with different types of advanced cancers. ART4215 is an oral targeted therapy that is designed to keep cancer cells from repairing DNA damage. 

More info
Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors

Treatment
Advanced solid tumors

Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors

This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes linked to DNA damage repair. The study will look at response to treatment with the drug ART0380 in combination with the chemotherapy agent, gemcitabine. 

More info
CYH33 in Combination With Olaparib in Patients With Advanced Solid Tumors and DNA Damage Repair Mutations

Treatment
Advanced solid tumors

Testing the New Targeted Therapy CYH33 in Combination With the PARP Inhibitor Olaparib in People With Advanced Solid Tumors and DNA Damage Repair Mutations

This study will look at safety and effectiveness of the targeted therapy CYH33 combined with the PARP inhibitor olaparib in people with advanced cancers and a DNA damage repair (DDR) gene mutation whose cancer got worse on, or after receiving a PARP inhibitor. The study will also enroll people with recurrent, platinum resistant ovarian cancer. In addition to safety and efficacy, the study will test whether the combination of CYH33 and olaparib can block tumor growth and overcome a patient’s resistance to PARP inhibitor treatment.

More info
Olaparib, Palbociclib and Fulvestrant for BRCA-Associated, ER/PR-Positive, Her2-Negative Metastatic Breast Cancer

Treatment

HOPE: Olaparib, Palbociclib and Fulvestrant for BRCA-Associated, ER/PR-Positive, Her2-Negative Metastatic Breast Cancer

The goal of this study is to find the best dose and measure side effects of palbociclib when given together with olaparib and fulvestrant, in treating people with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer who have a BRCA1 or BRCA2 mutation. Palbociclib and Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Fulvestrant is a type of treatment that may prevent breast cancer cell growth by blocking estrogen and progesterone receptor stimulation.

More info
Olaparib Expanded - Treating Metastatic Breast Cancer in People without gBRCA Mutations

Treatment

A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)

Olaparib Expanded is a study looking at whether the drug Olaparib is effective treatment for people with certain types of metastatic breast cancer.  Olaparib belongs to a class of drugs known as PARP inhibitors. PARP inhibitors are particularly effective for treating tumors in people with an inherited BRCA mutation. This study is looking at whether olaparib is also effective for treating metastatic breast cancer in people who do not have an inherited BRCA mutation. Currently the study is only recruiting people with an inherited PALB2 mutation or people who test negative for an inherited mutation in BRCA1 or BRCA2 but have an acquired (somatic) BRCA1 or BRCA2 mutation found on tumor testing. 

More info
Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations

Treatment

Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations

This is a study for patients with metastatic breast cancer who do not have an inherited mutation in BRCA1 or BRCA2 but who are are found to have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation) found through liquid biopsy. Patients are treated with talazoparib, a well-tolerated oral PARP inhibitor that targets the BRCA1/2 mutation to determine whether this treatment (which is already approved for germline BRCA1/2 carriers) is effective in this population.

More info
A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients (E-Reach)

Treatment

A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients

Genetic testing can be helpful to identify potential targeted treatments for some patients with metastatic cancer. But some patients have a hard time getting easy and fast testing. This study is looking at using web options to increase access to testing AND patients in this study can get genetic counseling and testing in their home! For more information visit  the E-Reach registration page

More info
RADCOMP: A Study at the Heart of Breast Cancer Treatment

Treatment

Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive nodal Radiation: A Radiotherapy Comparative Effectiveness Trial

The RadComp Study, short for Radiotherapy Comparative Effectiveness, is a nationwide clinical study comparing two FDA approved radiation therapies for the treatment of breast cancer, PHoton Therapy vs. PRoton Therapy. With any radiation treatment to the breast, the heart may be exposed to radiation potentially resulting in heart problems in the future. Both Photon and Proton therapies are FDA approved; however, to date doctors do not know which therapy is better or worse in terms of reducing side effects and promoting length and quality of life after radiation.

We hope to learn: The effectiveness of proton vs. photon therapy in reducing major cardiovascular events and how treatment affects patient’s quality of life, such as financial burden, fatigue, and anxiety. These objectives were chosen as study priorities by breast cancer patients themselves.

More info
Additional Results on Clinicaltrials.gov Treatment + Breast Cancer
476 results
Clinical Trial Official Title
NCT05464667 Preoperative Irradiation for Stage I Breast Cancer
NCT03643861 RAD 1802: Pilot Trial of Dose Adapted Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
NCT05528133 Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
NCT03043794 Study of Stereotactic Radiotherapy for Breast Cancer
NCT02958774 Hypofractionated Radiation Therapy for Patients With Breast Cancer Receiving Regional Nodal Irradiation
NCT04990921 Study of Palliative Radiation Combined With Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer
NCT04360330 SABER Study for Selected Early Stage Breast Cancer
NCT05436808 Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer
NCT05472792 Comparison of Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN)
NCT03460067 Omission of Radiation in Patients With Her-2 Positive Breast Cancer
NCT04454528 BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy
NCT05591547 Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen for patIents With Favorable Risk breaSt cancEr
NCT04648904 Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer
NCT03345420 Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer
NCT04040569 A Phase I Dose Escalation Study of Single Fraction Ablative Pre-operative Partial Breast (S-PBI) for Early Stage Breast Cancer
NCT03945721 A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
NCT04849871 Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma
NCT04923542 Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
NCT04965688 Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition
NCT02977468 Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
NCT04234386 GammaPod Dose Escalation Radiation for Early Stage Breast Cancer
NCT04837209 Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
NCT05774678 Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation
NCT05731791 Trial to Compare MRI-guided Precision Prone Irradiation (PPI) Versus CT-guided Breast Irradiation
NCT03909282 Phase 2 Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
NCT05288777 Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
NCT03981718 Adipose-Induced Regeneration of Breast Skin to Treat Post-Mastectomy Radiation Injury in Breast Cancer Patients
NCT04443413 Assessing the Rate of Complications in X-Ray Therapy Versus Proton Beam Radiation Therapy After Breast Conserving Surgery or Mastectomy in Treating Patients With Breast Cancer
NCT03789097 Vaccination With Flt3L, Radiation, and Poly-ICLC
NCT05456373 Intraoperative Use of ClearEdge Device in Breast Conserving Surgery
NCT01245712 Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
NCT05289466 Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With Prior History of Chest Wall Radiation.
NCT05245812 Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy
NCT02917421 Accelerated Radiation Therapy (ART) to the Breast and Nodal Stations
NCT04959474 SABR-CaRe in Early Stage Breast Cancer
NCT05340673 Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer
NCT05269160 Topical Dermaprazole for Radiation Dermatitis in Breast Cancer and Head and Neck Cancer Patients (TOPAZ)
NCT04175210 Prospective Randomized Study of Accelerated Radiation Therapy (PRART)
NCT03979508 Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
NCT02926729 Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
NCT03561454 An Investigator Initiated Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft® Axxent® eBx System
NCT03216421 Intraoperative Radiation Therapy (IORT) in DCIS
NCT02807597 Real-time Intraoperative Breast Cancer Visualization for Margin Assessment
NCT05130801 A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery
NCT05710328 Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
NCT06006806 Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy
NCT03768492 Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy
NCT04233385 Myofascial Massage for Pain and Immobility Following Breast Cancer Surgery
NCT04272801 Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer
NCT03796273 Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
NCT01185132 Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
NCT04225585 Well-Being After Breast Cancer Surgery
NCT02927912 Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction
NCT05892068 A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain
NCT04563507 Combined Immunotherapies in Metastatic ER+ Breast Cancer
NCT04371913 Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study
NCT03546686 Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer
NCT03990610 An Investigational Surgical Procedure (Vascularized Lymph Node Transfer) in Reducing the Risk of Lymphedema in Patients With Breast Cancer Undergoing Breast Reconstruction
NCT04815083 Fluorescence Imaging of Carcinoma During Breast Conserving Surgery
NCT05351424 AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc
NCT03488693 Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
NCT05705401 Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
NCT05422794 Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
NCT05929768 Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT04616248 In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
NCT04993313 Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study
NCT05178927 UFPTI 2105-BR05: Improving Breast Radiotherapy Setup and Delivery Using Mixed-Reality Visualization
NCT03765983 GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
NCT04588545 Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
NCT01766297 Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
NCT04852887 De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NCT04270149 Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer
NCT04020575 Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
NCT05325632 Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
NCT02564848 Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65
NCT04427293 Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
NCT01570998 Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery
NCT05412225 A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
NCT04329065 Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
NCT05447910 Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT05378464 Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
NCT02760030 Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery
NCT04368702 CONFIRM: Magnetic Resonance Guided Radiation Therapy
NCT04674306 Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer
NCT05190770 A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer
NCT05812924 A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause
NCT05081492 CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer
NCT05226663 A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer
NCT04998682 Prospective Evaluation of Targeted Axillary Dissection (TAD)
NCT03598257 Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
NCT04149522 Evaluation of Mepitel Film® in Preventing Epidermitis in Patients Receiving Radiation Therapy for Breast Cancer
NCT04899908 Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
NCT04348747 Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
NCT04871516 Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer
NCT02912312 Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
NCT03804944 Converting HR+ Breast Cancer Into an Individualized Vaccine
NCT04120246 Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
NCT04683679 A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
NCT04521764 A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
NCT04108858 Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
NCT02945579 Eliminating Surgery or Radiotherapy After Systemic Therapy in Treating Patients With HER2 Positive or Triple Negative Breast Cancer
NCT02603341 Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
NCT04443348 Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
NCT05142358 A Prospective Study to Evaluate Continuous Positive Airway Pressure Devices to Reduce Pulmonary Dose
NCT05457842 A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery
NCT05534438 A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
NCT05807074 Impact of Topical Tranexamic Acid in Breast Reconstruction
NCT04009044 Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast
NCT04879849 A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
NCT04946864 A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
NCT05455658 STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
NCT05549505 A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
NCT04389281 X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
NCT04440982 Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients
NCT05464082 Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
NCT04084730 Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
NCT04989504 Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy
NCT05098210 Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer
NCT05376878 An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
NCT05809752 A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
NCT04568616 Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)
NCT03694756 TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
NCT04266249 CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
NCT03213041 Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
NCT05554211 Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage
NCT04003038 Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery
NCT04534010 Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts
NCT04049214 Perioperative Mindfulness Proposal
NCT04553770 Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
NCT05677802 Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
NCT04606030 LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)
NCT05633654 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
NCT04636710 Refining Local-Regional Therapy for IBC
NCT03808337 Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
NCT04947917 Axillary Lymph Node Tattoo Marking Study
NCT05595499 Treatment of Frailty With Fisetin (TROFFi) in Breast Cancer Survivors
NCT05395936 Mastectomy Flap Temperature Study
NCT05795101 TRUDI: TDXD+Durva in HER2+/Low IBC
NCT06058650 Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities
NCT04445844 INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study
NCT03596073 Topical Calcipotriene Treatment for Breast Cancer Immunoprevention
NCT04535323 Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer
NCT05219695 Medical Imaging and Thermal Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI)
NCT05568472 Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
NCT03572374 Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
NCT05074290 Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients
NCT03820141 Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
NCT05954143 Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
NCT05704283 3D Ultrasound for the Imaging of Axillary Lymph Nodes in Patients With Breast Cancer
NCT05023967 Metformin and Nightly Fasting in Women With Early Breast Cancer
NCT05319873 Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
NCT05673200 Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
NCT03696030 HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
NCT03742102 A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
NCT05557877 Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
NCT04197687 TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
NCT04824027 Breast Elasticity Imaging During Neoadjuvant Chemotherapy
NCT05313191 Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
NCT05768139 First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT04784715 Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
NCT03796559 Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
NCT03801369 Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer
NCT03095352 Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
NCT05113927 Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.
NCT04711824 Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
NCT03179904 FASN Inhibitor TVB-2640 and Trastuzumab in Combination With Paclitaxel or Endocrine Therapy for the Treatment of HER2 Positive Metastatic Breast Cancer
NCT03535506 Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery
NCT04397185 Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer
NCT03351348 Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
NCT04514484 Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
NCT04647916 Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
NCT03747120 Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab
NCT05190978 Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction
NCT04072393 Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers
NCT04677816 Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
NCT03321045 Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
NCT05291507 Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
NCT05837767 A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NCT05744557 Vapocoolant Analgesia for Breast Lymphoscintigraphy
NCT04768426 Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
NCT03272334 Her2-BATS and Pembrolizumab in Metastatic Breast Cancer
NCT04965064 Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
NCT04692831 Testing a New Imaging Agent to Identify Cancer
NCT04796220 Focused Ultrasound and Gemcitabine in Breast Cancer
NCT05770531 Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
NCT05629585 A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT04282044 Study of CRX100 in Patients With Advanced Solid Tumors
NCT05146297 Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
NCT03739931 Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
NCT05720039 Robotic vs. Open NSM for Early Stage Breast Cancer
NCT03960463 EO2 Oxygen Delivery To Study Success Rate of Surgically Closed Wounds
NCT03504488 CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
NCT05076760 Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)
NCT04147494 Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
NCT04265872 Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
NCT04090398 Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones
NCT05203445 A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer
NCT05747794 Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy
NCT03428802 Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
NCT03303846 Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients
NCT05232916 Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
NCT05144698 RAPA-201 Therapy of Solid Tumors
NCT04144023 A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
NCT05807126 Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations
NCT04673448 Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
NCT05703269 Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
NCT05633979 Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
NCT04294628 Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer
NCT04650256 Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences
NCT04756765 Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer
NCT05694364 Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
NCT04891068 BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
NCT03449238 Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
NCT03562637 Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
NCT04478279 A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT05693766 Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
NCT05269381 Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT03075072 Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial
NCT04549571 Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions
NCT05069038 Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy
NCT04588246 Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NCT03606967 Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
NCT04315233 Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
NCT05545150 Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study
NCT05453825 A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
NCT04187898 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
NCT05163223 Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer
NCT04986579 Scalp Cooling in MBC
NCT05078398 Postoperative Opt-In Narcotics Treatment in Breast
NCT04699630 A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
NCT03328026 Combination Study of SV-BR-1-GM With Retifanlimab
NCT05020574 Microbiome and Association With Implant Infections
NCT03025035 Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
NCT05183126 Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer
NCT04090567 Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
NCT03742245 Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
NCT04243616 Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer
NCT01174121 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT04669301 Memory and Attention Adaptation Training-Geriatrics (MAAT-G) Phase II
NCT04134884 Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer
NCT05218044 Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
NCT04714983 DNX-2440 for Resectable Colorectal Liver Metastasis
NCT03740256 Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
NCT05924152 A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib
NCT04704661 Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT05607004 (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
NCT05092373 Tumor Treating Fields Therapy in Combination With Chemotherapy for the Treatment of Advanced Solid Tumors Involving the Abdomen or Thorax
NCT05748834 Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
NCT05877599 A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT05826964 Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
NCT05113251 Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
NCT05553522 Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer
NCT05675579 A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)
NCT05746897 A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
NCT05458674 A Phase II Study of the Safety, Tolerability and Antitumor Activity of Tucatinib in Combination With Eribulin and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
NCT04222413 Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
NCT05305924 Fulvestrant+Abemaciclib With or Without Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
NCT05963984 A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants
NCT05812807 Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT04703920 Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
NCT03971409 Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
NCT04475640 Cancer Genetic Testing in Ethnic Populations
NCT04457596 T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
NCT05035836 A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
NCT02993159 Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
NCT04246671 TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
NCT04644068 Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT05101564 Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer
NCT03589339 NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
NCT04205903 Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
NCT05524584 Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
NCT04102436 Non-Viral TCR Gene Therapy
NCT05150652 Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
NCT02830724 Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT05095207 Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
NCT04895358 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04174352 FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
NCT06042569 Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
NCT05020860 Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
NCT05256745 RAGE Inhibition to Decrease Therapy Cardiotoxicity in Women With Early Breast Cancer
NCT04722692 Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
NCT03435952 Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
NCT05274451 A Study to Investigate LYL797 in Adults With Solid Tumors
NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial
NCT05111561 Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
NCT04711252 A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04660929 CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
NCT02476786 Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
NCT03685331 HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
NCT05198843 Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body
NCT03990896 Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
NCT03934905 Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction
NCT06052852 Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies
NCT04345913 Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer
NCT05585034 Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
NCT03671044 A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
NCT04787042 Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
NCT05655598 TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
NCT03604315 Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
NCT04039230 Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
NCT03941730 Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
NCT04491942 Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
NCT04494945 Identifying and Caring for Individuals With Inherited Cancer Syndrome
NCT05608252 VS-6766+Abema+Fulv in Met HR+/HER- BC
NCT02276443 Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
NCT04862585 Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
NCT04542135 Sulindac and Breast Density in Women at Risk of Developing Breast Cancer
NCT02095184 GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
NCT04442126 A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
NCT05230810 Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
NCT04614194 Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
NCT04886531 Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in Triple Positive Breast Cancers
NCT02422641 Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
NCT05251714 CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
NCT04967976 Breast Mesh Used in Two-staged Breast Reconstruction
NCT02694809 The PROMISE Study: Duavee in Women With DCIS
NCT04762979 Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
NCT05576077 A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
NCT04577963 A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
NCT03752398 A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
NCT05700669 Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors
NCT02872025 Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)
NCT03917381 GEN1046 Safety Trial in Patients With Malignant Solid Tumors
NCT02484404 Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
NCT04072952 A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
NCT05868226 PRE-I-SPY Phase I/Ib Oncology Platform Program
NCT05498155 Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
NCT05894239 A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05132582 A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT03975647 A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
NCT03368729 Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
NCT05384119 Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
NCT04550494 Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT03901469 A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer
NCT03832855 Assessing the Immunogenicity of pING-hHER3FL
NCT05261269 A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer
NCT05383196 Onvansertib + Paclitaxel In TNBC
NCT04841148 Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
NCT04964934 Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
NCT05259696 Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
NCT03412877 Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
NCT05029999 CD40 Agonist, Flt3 Ligand, and Chemotherapy in Triple Negative Breast Cancer
NCT05464810 Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT03344965 Olaparib In Metastatic Breast Cancer
NCT04589468 Researching the Effect of Exercise on Cancer
NCT04584255 Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
NCT05451849 A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
NCT05383170 A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers
NCT05564377 Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT03238495 Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer
NCT04916002 A Trial to Find Out if Vidutolimod Together With Cemiplimab is Safe and if it Works in Adult Participants With Advanced Cancer or Metastatic Cancer
NCT01042379 I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT05759949 First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
NCT03090165 Ribociclib and Bicalutamide in AR+ TNBC
NCT05374512 A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT03424005 A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT03412643 Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
NCT05207709 Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
NCT05307705 A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
NCT04230109 Sacituzumab Govitecan In TNBC
NCT04849364 Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
NCT05483491 KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
NCT04958785 Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT04873362 A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
NCT04740918 A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
NCT05840211 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT03006172 To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
NCT05296798 A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05382286 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT04893109 ATEMPT 2.0: Adjuvant T-DM1 vs TH
NCT05852691 A Study of RO7247669 + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
NCT04567420 DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT05966584 A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer
NCT05774951 A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05501886 Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05654623 A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer.
NCT05382299 Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer
NCT04862663 Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04622319 A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
NCT05646862 A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT04906395 Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
NCT04191499 A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT05090358 Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
NCT05751668 Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)
NCT05323955 Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
NCT02206984 Endocrine Response in Women With Invasive Lobular Breast Cancer
NCT02264678 Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
NCT05645380 Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
NCT04802759 A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
NCT03746431 A Phase 1/2 Study of [225Ac]-FPI-1434 Injection
NCT03616587 Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
NCT05514054 A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05306340 A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
NCT04669587 ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)
NCT05239143 P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
NCT04569747 A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
NCT05467891 Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT05554354 Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer, A ComboMATCH Treatment Trial
NCT02488967 Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT04425018 MARGetuximab Or Trastuzumab (MARGOT)
NCT04468061 Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
NCT04150042 SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells
NCT05169567 Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
NCT04975308 A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT05262400 A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
NCT05765851 A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
NCT04448886 Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
NCT05417594 Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
NCT03367572 Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
NCT05216432 First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
NCT05563220 Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
NCT05161195 Roll-over Study to Allow Continued Access to Ribociclib
NCT05501769 ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
NCT05082610 A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab
NCT03930680 Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane
NCT05891171 Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
NCT05909397 A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer
NCT05150691 A Study of DB-1303 in Advanced/Metastatic Solid Tumors
NCT04332653 NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NCT04180371 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT04991480 A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
NCT05035407 T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
NCT05000294 Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
NCT03011684 Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
NCT05277051 First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT04042701 DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
NCT04726332 Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
NCT04659603 Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
NCT03845166 A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT05593094 A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors
NCT02632448 A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT04319757 ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
NCT04771520 Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
NCT04278144 A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
NCT04561362 Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumor Malignancies
NCT05252390 NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NCT05226871 Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
NCT05311618 Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NCT05887492 Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT04553133 PF-07104091 as a Single Agent and in Combination Therapy
NCT04570956 Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ
NCT04143711 Study of DF1001 in Patients With Advanced Solid Tumors
NCT04742959 Study of TT-00420 Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
NCT04389632 A Study of SGN-B6A in Advanced Solid Tumors
NCT04606446 Study of PF-07248144 in Advanced or Metastatic Solid Tumors
NCT05708950 A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
NCT05252416 (VELA) Study of BLU-222 in Advanced Solid Tumors
NCT04586335 Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
NCT05650879 ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
NCT04925284 Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
NCT05215574 Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NCT05169437 Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
NCT05070247 A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
NCT04913337 Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)
NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
NCT04254107 A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
NCT04557449 Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT03568656 Study to Evaluate CCS1477 in Advanced Tumours
NCT05107674 A Study of NX-1607 in Adults With Advanced Malignancies
NCT05898399 Study of ART6043 in Advanced/Metastatic Solid Tumors Patients
NCT05086692 A Beta-only IL-2 ImmunoTherapY Study
NCT04895709 A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
NCT03678883 9-ING-41 in Patients With Advanced Cancers
NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT04300556 A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT05716295 A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
NCT04373564 Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
NCT05537740 A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
NCT03674567 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
NCT05888831 A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
NCT05500508 Oral AMXT 1501 Dicaprate in Combination With IV DFMO
NCT04262466 Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
NCT04794699 Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Research Search Tool Sponsored By:

Merck & Co., Inc.
Mike & Patti Hennessy Foundation